BACKGROUND: Lung transplantation, in patients with end-stage lung disease, is limited by chronic rejection, which occurs with an incidence and severity exceeding most other transplanted organs. Alloimmune responses play an important role in progression to chronic rejection that manifests as bronchiolitis obliterans syndrome (BOS), but no biomarker can currently predict the progression to BOS. Studies in animal models suggest that intragraft T regulatory cells (Tregs) are important in maintaining transplantation tolerance, and FoxP3 is the protoypic Treg marker. METHODS: Leukocytes in blood and bronchoalveolar lavage (BAL) fluid were compared for expression of FoxP3 by flow cytometry in 14 stable lung transplant recipients and 6 lung transplant recipients who eventually developed BOS. RESULTS: Stable patients, compared with patients who subsequently developed BOS, consistently had a significantly increased percentage of FoxP3 cells among CD4 cells in BAL and greater levels of the Treg-attracting chemokine CCL22. These differences were observed in limited sequential analyses, before, at the time of acute rejection, and postacute rejection. In this pilot study, a threshold of 3.2% CD4/FoxP3 cells in the BAL distinguished stable recipients from those subsequently developing BOS within the first 2 years posttransplantation. CONCLUSION: The proportion of FoxP3 cells among CD4 cells in BAL may help to predict lung allograft outcome and guide therapeutic immunosuppression in lung transplant recipients.
BACKGROUND: Lung transplantation, in patients with end-stage lung disease, is limited by chronic rejection, which occurs with an incidence and severity exceeding most other transplanted organs. Alloimmune responses play an important role in progression to chronic rejection that manifests as bronchiolitis obliterans syndrome (BOS), but no biomarker can currently predict the progression to BOS. Studies in animal models suggest that intragraft T regulatory cells (Tregs) are important in maintaining transplantation tolerance, and FoxP3 is the protoypic Treg marker. METHODS: Leukocytes in blood and bronchoalveolar lavage (BAL) fluid were compared for expression of FoxP3 by flow cytometry in 14 stable lung transplant recipients and 6 lung transplant recipients who eventually developed BOS. RESULTS: Stable patients, compared with patients who subsequently developed BOS, consistently had a significantly increased percentage of FoxP3 cells among CD4 cells in BAL and greater levels of the Treg-attracting chemokine CCL22. These differences were observed in limited sequential analyses, before, at the time of acute rejection, and postacute rejection. In this pilot study, a threshold of 3.2% CD4/FoxP3 cells in the BAL distinguished stable recipients from those subsequently developing BOS within the first 2 years posttransplantation. CONCLUSION: The proportion of FoxP3 cells among CD4 cells in BAL may help to predict lung allograft outcome and guide therapeutic immunosuppression in lung transplant recipients.
Authors: Thangamani Muthukumar; Darshana Dadhania; Ruchuang Ding; Catherine Snopkowski; Rubina Naqvi; Jun B Lee; Choli Hartono; Baogui Li; Vijay K Sharma; Surya V Seshan; Sandip Kapur; Wayne W Hancock; Joseph E Schwartz; Manikkam Suthanthiran Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Creg J Workman; Andrea L Szymczak-Workman; Lauren W Collison; Meenu R Pillai; Dario A A Vignali Journal: Cell Mol Life Sci Date: 2009-04-24 Impact factor: 9.261
Authors: C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs Journal: Nat Genet Date: 2001-01 Impact factor: 38.330
Authors: Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou Journal: Nat Med Date: 2004-08-22 Impact factor: 53.440
Authors: Joseph L Bobadilla; Robert B Love; Ewa Jankowska-Gan; Qingyong Xu; Lynn D Haynes; Ruedi K Braun; Mary S Hayney; Alejandro Munoz del Rio; Keith Meyer; Daniel S Greenspan; Jose Torrealba; Kathleen M Heidler; Oscar W Cummings; Takekazu Iwata; David Brand; Robert Presson; William J Burlingham; David S Wilkes Journal: Am J Respir Crit Care Med Date: 2008-01-03 Impact factor: 21.405
Authors: Iris Lee; Liqing Wang; Andrew D Wells; Martin E Dorf; Engin Ozkaynak; Wayne W Hancock Journal: J Exp Med Date: 2005-04-04 Impact factor: 14.307
Authors: Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn Journal: Semin Immunopathol Date: 2011-01-27 Impact factor: 9.623
Authors: A W M Paantjens; E A van de Graaf; J M Kwakkel-van Erp; T Hoefnagel; D A van Kessel; J M M van den Bosch; H G Otten Journal: Clin Exp Immunol Date: 2011-10 Impact factor: 4.330
Authors: Andrew E Gelman; Andrew J Fisher; Howard J Huang; Maher A Baz; Ciara M Shaver; Thomas M Egan; Micheal S Mulligan Journal: J Heart Lung Transplant Date: 2017-07-24 Impact factor: 10.247
Authors: S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio Journal: Semin Respir Crit Care Med Date: 2013-07-02 Impact factor: 3.119
Authors: J R Greenland; N P Jewell; M Gottschall; N N Trivedi; J Kukreja; S R Hays; J P Singer; J A Golden; G H Caughey Journal: Am J Transplant Date: 2014-02-11 Impact factor: 8.086